C-Bemnifosbuvir + ruzasvir + omeprazole

**C-Bemnifosbuvir + ruzasvir + omeprazole** refers to a fixed combination regimen under clinical investigation for the treatment of chronic hepatitis C virus (HCV) infection. The core antiviral combination, bemnifosbuvir and ruzasvir, are direct-acting antiviral agents (DAAs): bemnifosbuvir is a potent, selective, orally available guanosine nucleotide analog prodrug that inhibits HCV nonstructural protein 5B (NS5B), an RNA-dependent RNA polymerase essential for viral RNA replication; ruzasvir is a potent, pan-genotypic NS5A inhibitor targeting HCV replication complex assembly and viral replication[1][3][5]. Omeprazole, a proton pump inhibitor, is included in clinical interaction studies to evaluate any pharmacokinetic or pharmacodynamic effects on the antiviral agents, as acid-reducing agents may alter the absorption of co-administered drugs. The combination aims to provide an effective, short-duration, all-oral regimen for adults with HCV, with current clinical development focused on establishing the impact of omeprazole on bemnifosbuvir/ruzasvir pharmacokinetics and efficacy[7][9][10].

Other names

C-Bemnifosbuvir + ruzasvir + omeprazolebemnifosbuvir/ruzasvir + omeprazole